TranS1's two-level spinal fusion product:
This article was originally published in Clinica
TranS1 has received US FDA 510(k) clearance for its AxiaLIF 2L two-level percutaneous lumbar fusion system. The Wilmington, North Carolina company's AxiaLIF (axial lumbar interbody fusion) single-level approach was cleared by the FDA in 2004. The older product allows surgeons to access the L5-S1 vertebrae via a one-inch (2.54cm) opening, while AxiaLIF 2L is designed to treat degenerative disc disease at both the L5-S1 and L4-L5 lumbar discs through a single 1.5 inch (3.81cm) incision. TranS1 said there were similar advantages with both minimally-invasive procedures - early release from hospital, rapid return to normal activities and long-term reduction of leg and back pain. AxiaLIF 2L is already available in Europe.
You may also be interested in...
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.
UK start up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country.